Patterson R, Grammer L C
Ann Allergy Asthma Immunol. 1999 Apr;82(4):315-6. doi: 10.1016/S1081-1206(10)63280-2.
Efficacy of standard IT to reduce medications and symptoms by at least 50% has been demonstrated multiple times. Reports of negative studies of IT deserve only evaluation of why the study design failed to demonstrate efficacy. Emphasis in the US and worldwide should be on education on the appropriate use of allergen IT, improvements in IT therapy, and preparation for the increased demand for allergists-immunologists as Fellowship training programs decline in numbers and individual training slots decrease.
标准免疫疗法（IT）将药物和症状减轻至少50%的疗效已得到多次证实。关于免疫疗法的负面研究报告只值得评估其研究设计为何未能证明疗效。在美国和全球范围内，重点应放在关于过敏原免疫疗法的正确使用的教育、免疫疗法的改进，以及随着研究员培训项目数量减少和个人培训名额减少，为满足对过敏症专科医生-免疫学家不断增加的需求做好准备。
